News & Updates

Show Multimedia Only
Brolucizumab for neovascular age-related macular degeneration holds up in real world

Brolucizumab for neovascular age-related macular degeneration holds up in real world

30 Sep 2022

The use of brolucizumab for the treatment of patients with neovascular age-related macular degeneration (nAMD) in the real-world setting appears to be effective and safe, consistent with data from pivotal trials, as reported in a study.

30 Sep 2022